Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1254 daily bars · split adjusted
Current price $10.68
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jul 15, 26 |
Daily · Wilder smoothing
| Mizuho |
| maintain |
| Outperform |
| Outperform |
| May 7, 26 | Mizuho | maintain | Outperform | Outperform |
| May 7, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Apr 13, 26 | Mizuho | maintain | Outperform | Outperform |
| Mar 26, 26 | Cantor Fitzgerald | downgrade | Overweight | Neutral |
| May 8, 25 | Raymond James | maintain | Strong Buy | Strong Buy |
| Mar 4, 25 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Nov 8, 24 | Raymond James | maintain | Strong Buy | Strong Buy |
| Nov 8, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 58.17 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 70.31 | Oscillator | Neutral |
| Williams %R (14) | -48.15 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.36 (Hist 0.03) | Oscillator | Strong Buy |
| Average Directional Index (14) | 25.09 (+DI 23.8 / -DI 16.9) | Trend | Strong Buy |
| EMA 20 | 10.44 | MA | Buy |
| SMA 20 | 10.40 | MA | Buy |
| EMA 50 | 9.96 | MA | Strong Buy |
| SMA 50 | 9.83 | MA | Strong Buy |
| SMA 200 | 11.12 | MA | Strong Sell |
FY2024 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
Adma Biologics (ADMA) closed the most recent trading day at $11.24, moving +1.49% from the previous trading session.
Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Myriad Genetics (NASDAQ: MYGN - Get Free Report) and ADMA Biologics (NASDAQ: ADMA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. Earnings and Valuation This table compares Myriad Genetics
In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.
Recently, Zacks.com users have been paying close attention to Adma Biologics (ADMA). This makes it worthwhile to examine what the stock has in store.
Shares of ADMA Biologics Inc (NASDAQ: ADMA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month
In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | 0.16 | 0.16 | Miss -2.0% | $124.4M |
| May 6, 2026 | 0.19 | 0.19 | Miss -1.7% | $114.5M |
| Feb 25, 2026 | 0.19 | 0.20 | Beat 8.1% | $139.2M |
| Nov 5, 2025 | 0.16 | 0.16 | Beat 0.0% | $134.2M |
| Aug 6, 2025 | 0.14 | 0.15 | Beat 7.1% | $122.0M |
| May 7, 2025 | 0.16 | 0.14 | Miss -12.5% | $114.8M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| SC 13G | Aug 7, 2026 | 2026-08-07 08:23:20 | View |
| 10-Q | Aug 5, 2026 | 2026-08-05 17:16:08 | View |
| 8-K | Aug 5, 2026 | 2026-08-05 16:10:51 | View |
| 4 | Jul 28, 2026 | 2026-07-28 21:00:34 | View |
| 4 | Jul 17, 2026 | 2026-07-17 21:00:20 | View |
| 8-K | Jun 2, 2026 | 2026-06-02 16:05:29 | View |
| 4 | May 28, 2026 | 2026-05-28 16:05:25 | View |
| 4 | May 14, 2026 | 2026-05-14 07:00:16 | View |
| 4 | May 12, 2026 | 2026-05-12 17:22:51 | View |
| 10-Q | May 6, 2026 | 2026-05-06 17:16:25 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jul 24, 26 | Kestenberg-Messina Kaitlin M. | officer: COO and SVP, Compliance | F-InKind | 3,177 @ $8.37 | $26.59K |
| Jul 16, 26 |
| Kohler Terry |
| officer: CFO and Treasurer |
| A-Award |
| 85,130 |
| — |
| Jul 16, 26 | Kohler Terry | officer: CFO and Treasurer | A-Award | 136,363 @ $8.81 | $1.20M |
| May 27, 26 | Grossman Jerrold B | director | P-Purchase | 6,400 @ $7.91 | $50.62K |
| May 12, 26 | Grossman Jerrold B | director | P-Purchase | 12,500 @ $8.01 | $100.1K |
| May 11, 26 | Grossman Jerrold B | director | P-Purchase | 12,500 @ $8.01 | $100.1K |
| Apr 1, 26 | Kestenberg-Messina Kaitlin M. | officer: COO and SVP, Compliance | F-InKind | 20,362 @ $9.11 | $185.5K |
| Mar 13, 26 | Guiheen Lawrence P. | director | M-Exempt | 30,000 @ $3.66 | $109.8K |
TTM vs. 5-year historical average (annual ratios)
| Metric | ADMA | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 14.8x | 0.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 13.4x | EPS est. 0.80 | In line |
| Price / Book | 6.0x | 6.9x | In line |
| Price / Sales | 4.7x | 5.8x | Discount |
| EV / EBITDA | 10.6x | 47.7x | Discount |
| Return on equity | 39.6% | — | Top tier |
| Gross margin | 64.7% | 33.5% | Above hist. |
| Debt / Equity | 0.50 | 0.64 | Conservative |
| Piotroski / Altman Z | 6/9 | Z 7.67 | Safe zone |
Discounted cash flow model